ScoreWhy is ERIS Lifesciences Ltd ?
1
High Management Efficiency with a high ROCE of 19.25%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.88 times
3
Poor long term growth as Operating profit has grown by an annual rate 15.22% of over the last 5 years
4
Flat results in Dec 24
- INTEREST(9M) At Rs 177.01 cr has Grown at 162.43%
- PAT(HY) At Rs 175.22 cr has Grown at -22.53%
5
Stock is technically in a Bullish range
- The technical trend has improved from Mildly Bullish on 09-Apr-25
- Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
6
With ROCE of 11.1, it has a Expensive valuation with a 3.9 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 59.09%, its profits have fallen by -14.8%
7
High Institutional Holdings at 26.42%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
8
Market Beating performance in long term as well as near term
- Along with generating 59.09% returns in the last 1 year, the stock has outperformed BSE 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ERIS Lifescience should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Drugs should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ERIS Lifescience for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
ERIS Lifescience
61.27%
1.74
34.03%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.51%
EBIT Growth (5y)
15.22%
EBIT to Interest (avg)
77.06
Debt to EBITDA (avg)
1.12
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.64
Tax Ratio
19.42%
Dividend Payout Ratio
0
Pledged Shares
18.51%
Institutional Holding
26.42%
ROCE (avg)
19.87%
ROE (avg)
18.53%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
55
Industry P/E
33
Price to Book Value
6.58
EV to EBIT
33.36
EV to EBITDA
22.71
EV to Capital Employed
3.94
EV to Sales
7.57
PEG Ratio
NA
Dividend Yield
0.55%
ROCE (Latest)
11.06%
ROE (Latest)
12.57%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
NET SALES(9M)
Higher at Rs 2,188.34 cr
-13What is not working for the Company
INTEREST(9M)
At Rs 177.01 cr has Grown at 162.43%
PAT(HY)
At Rs 175.22 cr has Grown at -22.53%
Loading Valuation Snapshot...
Here's what is working for ERIS Lifescience
Net Sales - Quarterly
At Rs 727.45 cr has Grown at 49.59%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Here's what is not working for ERIS Lifescience
Profit After Tax (PAT) - Quarterly
At Rs 83.63 cr has Fallen at -18.6%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Interest - Half Yearly
At Rs 116.64 cr has Grown at 24.88%
over previous Half yearly periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
